Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Score 1
2025 pubmed 4 citations

Comprehensive Study on Central Precocious Puberty: Molecular and Clinical Analyses in 90 Patients.

Narusawa. Hiromune H; Ogawa. Tomoe T; Yagasaki. Hideaki H; Nagasaki. Keisuke K; Urakawa. Tatsuki T; Saito. Tomohiro T; Soneda. Shun S; Kinjo. Saori S; Sano. Shinichiro S; Mamada. Mitsukazu M; Terashita. Shintaro S; Dateki. Sumito S; Narumi. Satoshi S; Naiki. Yasuhiro Y; Horikawa. Reiko R; Ogata. Tsutomu T; Fukami. Maki M; Kagami. Masayo M

Key Findings

  • 8 out of 90 patients (≈9%) had TS14, an imprinting disorder linked to early puberty.
  • 3 patients (≈3%) had MKRN3 genetic defects, often with a family history of early puberty in fathers.
  • No pathogenic variants were found in KISS1 or KISS1R genes.
  • TS14 patients were generally shorter and many were born small for gestational age.
  • (Epigenetic) genetic causes accounted for 12.2% of the central precocious puberty cases.

Practical Outcomes

  • If you or someone you know shows signs of unusually early puberty—especially if they were small at birth or have a dad who matured early—consider genetic testing for TS14 and MKRN3. The study doesn’t suggest any new use for kisspeptin-10, so there’s no direct protocol change for that peptide.

Summary

Researchers examined 90 kids with unusually early puberty and found that about 12% had genetic or epigenetic reasons, mainly a disorder called TS14 or defects in the MKRN3 gene. They did not find any harmful changes in the kisspeptin (KISS1) gene, which is the peptide you asked about.

Abstract

Defects in MKRN3, DLK1, KISS1, and KISS1R and some disorders, such as Temple syndrome (TS14), cause central precocious puberty (CPP). Recently, pathogenic variants (PVs) in MECP2 have been reported to be associated with CPP. We aimed to clarify the contribution of (epi)genetic abnormalities to CPP and clinical and hormonal features in each etiology. We conducted targeted sequencing for MKRN3, DLK1, MECP2, KISS1, and KISS1R and methylation analysis for screening of imprinting disorders such as TS14 associated with CPP in 90 patients with CPP (no history of brain injuries and negative brain magnetic resonance imaging) and collected their clinical and laboratory data. We measured serum DLK1 levels in 3 patients with TS14 and serum MKRN3 levels in 2 patients with MKRN3 genetic defects, together with some etiology-unknown patients with CPP and controls. We detected 8 patients with TS14 (6, epimutation; 1, mosaic maternal uniparental disomy chromosome 14; 1, microdeletion) and 3 patients with MKRN3 genetic defects (1, PV; 1, 13-bp deletion in the 5'-untranslated region [5'-UTR]; 1, microdeletion) with family histories of paternal early puberty. There were no patients with PVs identified in MECP2, KISS1, or KISS1R. We confirmed low serum MKRN3 level in the patient with a deletion in 5'-UTR. The median height at initial evaluation of TS14 patients was lower than that of all patients. Six patients with TS14 were born small for gestational age (SGA). (Epi)genetic causes were identified in 12.2% of patients with CPP at our center. For patients with CPP born SGA or together with family histories of paternal early puberty, (epi)genetic testing for TS14 and MKRN3 genetic defects should be considered.

Study Information

Provider

pubmed

Year

2025

Date

2025-03-17T00:00:00.000Z

DOI

10.1210/clinem/dgae666

Citations

4